Corona Remedies IPO Day 1 Live — Why the GMP and Early Signals Matter
Yes — Corona Remedies IPO is open for subscription from December 8, 2025, and early grey market data shows a GMP of ~₹290–₹365, implying a likely 25–35% listing-day pop if sentiment holds.
Key Takeaways
- Price band & issue details: IPO priced at ₹1,008–₹1,062 per share via a full Offer-For-Sale (OFS), raising ₹655.37 crore. Lot size: 14 shares; retail min. investment: ₹14,868.
- Grey Market Premium (GMP): Unofficial GMP trading around ₹290–₹365 indicates ~27–34 % expected listing gains.
- Strong anchor interest: Before opening, the IPO had attracted ₹195 crore from 15 anchor investors — a sign of institutional backing.
- Company fundamentals: In FY25, revenue rose ~18% to ₹1,196.4 cr, and PAT jumped ~65% to ₹149.4 cr, showing healthy growth ahead of listing.
IPO Overview — What’s on the Table
Key Dates & Structure
| Parameter | Detail |
|---|---|
| IPO Open | December 8, 2025 |
| IPO Close | December 10, 2025 |
| Offer Type | 100% Offer-for-Sale (OFS) — no fresh capital raised. |
| Price Band | ₹1,008 – ₹1,062 per share |
| Lot Size / Min Investment | 14 shares / ₹14,868 at upper band |
| Issue Size | ₹655.37 crore |
| Anchor Funding (pre-IPO) | ₹194.85 crore from 15 institutional investors |
| Expected Listing Date* | December 15, 2025 (on BSE & NSE) |
*Subject to regulatory and procedural clearance.
Grey Market Premium & What It Suggests
- Several unofficial market trackers show GMP between ₹290–₹365.
- With most recent upper price band at ₹1,062 — a GMP of ₹290 suggests a potential listing price around ₹1,350 → ~27% gain; a GMP of ₹365 points toward ~34–35% listing upside.
- That said: GMP is unregulated. It reflects sentiment, not guarantee. Treat as a rough signal, not a promise.
Company Snapshot: What Corona Remedies Brings to the Table
- Pharma company with focus on women’s health, cardio-diabeto (cardio + diabetes), urology, pain management, and other segments.
- For FY25: Revenue ₹1,196.4 crore; PAT ₹149.4 crore — a strong ~65% year-on-year profit jump.
- Its manufacturing capacity covers over 1,285 million units annually across 11 production lines; backward-integration underway for hormone APIs.
- Backed by PE-investor ChrysCapital — lends some institutional credibility.
Implication for investors: While the IPO will not raise fresh funds (being OFS), the underlying business appears profitable and growing. If fundamentals hold post-listing, it could find traction in pharma-focused portfolios.
Risks & What Investors Should Watch
- No fresh capital: As an OFS, Corona gets no cash from this IPO. Expansion, R&D or debt servicing won’t benefit. Gains go to existing shareholders.
- Valuation premium: GMP-driven listing expectations price in strong growth — any post-listing disappointment could lead to sharp corrections.
- Sector & competition risk: Indian pharma is crowded; future growth depends on constant innovation, supply-chain stability, regulation, and competition.
- GMP volatility: Grey-market values can swing hard; using them as sole decision driver is risky.
Should Retail Investors Subscribe? My Take
If you aim for listing-day gains, this IPO presents a compelling bet — strong GMP, growth fundamentals, institutional backing.
If you’re looking for long-term value, treat Corona Remedies as a moderately risky mid-cap pharma play: potentially rewarding, but execution, competition and absence of fresh capital create uncertainty.
Bottom line: For listing-gain seekers — reasonable. For long-term believers — only if you accept volatility and sector risks.
FAQ
A: No. GMP is unofficial and reflects sentiment in grey-market. Actual listing price will be driven by demand, supply, and general market mood.
A: Not always. OFS means the company doesn’t get fresh funds; it can’t expand or repay debt from IPO proceeds. That limits upside unless it grows via profits or acquisitions.
A: Expected listing date is December 15, 2025. But actual listing price depends on subscription, investor demand, and broader market conditions at that time.
